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Abstract
Background: Pulmonary arterial hypertension (PAH) is the leading cause of mortality in patients with systemic
sclerosis (SSc). We sought to determine the incidence, prevalence and risk factors for PAH development in a large
Australian SSc cohort.
Methods: PAH was diagnosed on right heart catheterisation (mPAP >25 and PAWP <15 mmHg at rest). Patients
with PH secondary to interstitial lung disease (ILD; defined as abnormal HRCT scan and FVC < 60 %) were excluded.
Summary statistics, chi-square tests, univariate and multivariable logistic regression along with post-estimation
diagnostics were used to determine the associations of different combinations of risk factors with PAH.
Results: Among 1579 SSc patients, 8.4 % (132 patients) were diagnosed with PAH over a mean (±SD) follow-up of
3.2 (±2.5) years. The incidence of PAH in this cohort was 0.7 % per annum. Of these, 68.9 % had limited disease
subtype (lcSSc). In multivariable regression analysis, the presence of anti-centromere antibody (ACA) (OR 1.6, 95 %
CI 1.1–2.5, p = 0.03), oesphageal stricture (OR 2.0, 95 % CI 1.2–3.3, p = 0.006), calcinosis (OR 1.9, 95 % CI 1.2–2.9, p = 0.
003), sicca symptoms (OR 1.6, 95 % CI 1.1–2.5, p = 0.03), mild ILD (OR 2.3, 95 % CI 1.5–3.7, p < 0.001) and digital
ulcers (OR 1.6, 95 % CI 1.0–2.4, p = 0.03) were predictive of PAH. This model had an area under the curve of 0.7 and
concordance of 91.8 %. When analysed by disease subtype, the presence of calcinosis (OR 2.2, 95 % CI 1.4–3.7, p = 0.01),
sicca symptoms (OR 2.6, 95 % CI 1.5–4.6, p = 0.001), mild ILD (OR 2.3, 95 % CI 1.4–3.8, p = 0.001) and digital ulcers (OR 1.9,
95 % CI 1.2–3.7, p= 0.01) were predictive of PAH in lcSSc; and oesophageal stricture (OR 4.4, 95 % CI 1.9–10.5, p = 0.001),
mild ILD (OR 2.8, 95 % CI 1.2–6.8, p = 0.02) and ACA (OR 5.2, 95 % CI 1.8–14.8, p = 0.002) were predictive of PAH in dcSSc.
Conclusions: The incidence and prevalence of PAH in this cohort are 0.7 % per annum and 8.4 %, respectively. The
clinical-serologic risk factors for PAH differ based on disease subtype. In both subtypes, mild ILD is associated with PAH,
suggesting the possibility of common pathogenic mechanisms underlying both of these disease manifestations. This
model identifies a subset of patients at an appreciably higher risk of developing PAH, who should be screened and
would in future, benefit from preventative therapies.
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Background
Systemic sclerosis (SSc) is a multisystem autoimmune
disease characterised by fibrosis of skin and internal
organs, vasculopathy and immune dysregulation. It is
classified into distinct subtypes based on the degree of
skin fibrosis, namely limited (lcSSc) and diffuse cutaneous
(dcSSc) subsets. SSc is a complex clinically heterogeneous
disease, the underlying aetiology of which is not fully
understood. It is presumed to occur in a genetically sus-
ceptible host after exposure to an environmental trigger
[1]. Currently there are no effective disease modifying
agents or cure.
Despite an improvement over the last three decades,
morbidity and mortality in SSc remain high. Survival is
well below age and gender matched controls, with an
overall standardised mortality ratio of 4.08 and a ten-
year survival of 75 % in a newly diagnosed patient with
diffuse disease [2].
Cardiorespiratory manifestations, namely pulmonary
arterial hypertension (PAH) and interstitial lung disease
(ILD), remain the leading causes of SSc-related deaths.
SSc-PAH, as diagnosed on right heart catheterisation
(mPAP >25 and PAWP <15 mmHg at rest), occurs with
a prevalence of 8–12 % and is associated with reduced
life expectancy [3]. The pathogenesis of SSc-PAH is un-
known, but thought to be a combination of endothelial
cell dysfunction and an imbalance of endothelial derived
vasoactive substances [1].
The difficulty with diagnosing SSc-PAH is that the
clinical manifestations are non-specific. Early in the disease
process, patients may remain asymptomatic. Later, they
may complain of lethargy, fatigue, exertional dyspnoea
and/or symptoms of right heart failure, by which time
PAH is likely to be moderate to severe, with an average
three-year survival of 40–50 % [4]. In addition to redu-
cing the quantity of life, PAH also impacts significantly
on the quality of these years of life, reflected by poor
patient reported health related quality of life scores [5].
Consequently, annual screening programs aimed at de-
tecting PAH in its early phases have been recommended
for all patients with SSc, to enable an earlier diagnosis of
PAH and early commencement of aggressive therapy with
the goal of prolonging life years and improving quality of
life [6]. These screening programs have been shown to be
cost effective [7]. In the last decade, with the introduction
of potent pulmonary vasodilator therapies, patients’ quality
of life and survival have improved [8].
Given the availability and potential of such agents, it is
important to identify patients who are at increased risk
of developing PAH. Certain hemodynamic characteristics
on transthoracic echocardiography (TTE) and reduced
diffusing capacity for carbon monoxide corrected for
haemoglobin (DLCOc) on pulmonary function testing
(PFT) point to the presence of PAH and are used in
screening algorithms for SSc-PAH, but no predictive
model based specifically on clinical manifestations and
antibody status has been reported.
We sought to determine the incidence, prevalence and




All patients were enrolled in the Australian Scleroderma
Cohort Study (ASCS) and fulfilled either the American
College of Rheumatology or Leroy and Medsger criteria
for SSc [9, 10]. The ASCS is a multi-center study of risk
and prognostic factors for cardiopulmonary outcomes in
SSc. It comprises 13 Australian centers and has been
approved by the human research ethics committees of
each of the participating hospitals (St. Vincent’s Hospital,
Melbourne, Royal Adelaide Hospital, Monash Health,
Royal Perth Hospital, The Queen Elizabeth Hospital,
Sunshine Coast Rheumatology, Prince Charles Hospital,
John Hunter Hospital, Royal North Shore Hospital, Royal
Prince Alfred Hospital, St George Hospital, Canberra
Rheumatology and the Menzies Research Institute
Tasmania). All patients provide written informed con-
sent at recruitment.
Inclusion and exclusion criteria
We included all consecutive adult (>18 years) SSc pa-
tients from the ASCS recruited between December 2007
and June 2015. All patients were screened annually for
PAH with PFTs and TTE. Any patient with a high risk
of PAH (defined as systolic pulmonary arterial pressure
(sPAPTTE) of at least 40 mmHg and/or DLCOc less than
50 % predicted with forced vital capacity (FVC) of more
than 85 % predicted (without adequate explanation on
high-resolution computer tomography (HRCT) of the
lung or ventilation-perfusion (V/Q) scan of lung or both)
underwent right heart catheterisation (RHC).
As per the current World Health Organization (WHO)
classification [11], patients were classified as having SSc-PAH
(WHO Group 1) if RHC-determined mean pulmonary
arterial pressure (mPAP) was at least 25 mmHg with a
pulmonary artery wedge pressure (PAWP) of ≤15 mmHg
with no more than mild ILD on HRCTand a FVC of more
than 60 % predicted. A patient was classified as having
PAH from the date of their first RHC confirming PAH.
Patients were excluded if they had WHO Group 2 or 3
pulmonary hypertension or group 1 pulmonary arterial
hypertension but with co-existing moderate-severe ILD
with a FVC <60 % and an abnormal HRCT (see below).
Patients were divided into two categories based on
their diagnosis of PAH: SSc patients with PAH and SSc
patients without PAH.
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Data collection
Patient demographics, clinical variables, cardiac and
pulmonary assessments were prospectively recorded.
All physical examination and investigation data were
collected within one month of the first RHC, before
starting pulmonary vasodilator therapy. TTE was per-
formed according to standardised procedures only at
tertiary centers. Pulmonary involvement was assessed
by clinical examination and PFT and HRCT if ILD was
suspected. All disease features were defined as present
ever from time of diagnosis. Sicca symptoms were de-
fined as dry eyes or dry mouth for more than four an-
nual reviews. ILD was defined based on characteristic
interstitial changes on HRCT which were performed
and interpreted by a radiologist at the tertiary hospital
with a specialised SSc clinic. Each HRCT scan was
graded based on total extent of lung involvement into
limited (<20 % involved) and extensive (>20 %). Those
where the disease extent was unclear were classified as
‘indeterminate’. All patients with indeterminate or ex-
tensive ILD were excluded from this study. Myocardial
disease was defined on endomyocardial biopsy or as
the presence of conduction defects, arrhythmia, right
ventricular or left ventricular dysfunction in the absence of
other causes. Pericardial effusions were defined on echocar-
diogram other than a small non-significant pericardial effu-
sion. Renal crisis was defined on a combination of any two
of the following three criteria, which included new onset
severe hypertension (≥180 mmHg systolic and/or ≥
100 mmHg) without an alternate aetiology, microan-
giopathic hemolytic anemia or rising creatinine. Gas-
tric antral vascular ectasia (GAVE), reflux oesophagitis
and oesophageal stricture were defined on endoscopy.
Bowel dysmotility was defined based on barium and
nuclear medicine studies, antibiotic response or char-
acteristic symptoms.
At each annual visit, patients completed a health re-
lated quality of life form (Medical Outcomes Study
Short form-36 (SF-36 form)) which is a validated tool
for measuring health related quality of life (HRQoL) in
patients with rheumatic conditions including SSc [12].
The classification of patients into lcSSc and dcSSc was
confirmed by reviewing their peak modified Rodnan
skin scores which has been shown to be a valid and reli-
able method for differentiating between SSc disease sub-
types [13].
Statistical analysis
Data are presented as mean ± standard deviation for
continuous variables and as number (percentage) for cat-
egorical variables. The difference in frequency was deter-
mined by using chi-square and Fisher’s exact tests. The
predictive accuracy of the models is presented as sensi-
tivity, specificity, positive (PPV) and negative predictive
values (NPV), with 95 % confidence intervals (CI). Negative
predictive accuracy requires the exclusion of PAH on RHC;
however it would not be feasible for all patients to undergo
such an invasive procedure. Thus, we defined no PAH as
those who do not fulfill ‘at risk of PAH criteria’, defined as
sPAP >/=40 mmHg and/or DLCOc <50 % and FVC >85 %
predicted. Summary statistics, univariable and multivariable
logistic regression were performed to determine the predic-
tors of PAH. Statistically significant variables (defined by a
p-value of <0.05) and or variables previously reported in
the literature to be predictors of PAH where included in
the multivariable analysis. Post-estimation diagnostics were
used to determine the associations of different combina-
tions of risk factors with PAH. Area under the curve and
goodness of fit and concordance were used to assess the
models. A two-tailed p value of not more than 0.05 was
considered statistically significant. All statistical analyses




Among 1579 SSc patients in the ASCS, 8.4 % (132 patients)
were diagnosed with WHO Group 1 PAH. The incidence
of PAH in this cohort was 0.7 % per annum. PAH occurred
more frequently in women and in the limited subtype, but
this did not reach statistical significance. At PAH diagnosis,
the mean (±SD) age was 62 (±10.5) years and the disease
duration from the first non-Raynaud’s manifestation was 14
(±12) years. The mean (±SD) follow-up of 3.2 (±2.5) years
from cohort entry. Disease duration at PAH diagnosis was
not significantly different between disease subtypes [lcSSc
15.3 (±12.4) years vs dcSSc 12.8 (±11.3) years, p = 0.40)].
There was no significant difference in the frequency of
anti-centromere pattern antinuclear antibody (ACA; de-
termined by immunofluorescence) or anti-phospholipid
antibodies (APLA; determined by ELISA) in patients
with and without PAH (Table 1). Anti-topoisomerase I
antibody (Scl-70; determined by ELISA) was more com-
mon in those without PAH (14.1 %,) than in those with
PAH (7.4 %), p = 0.04. Clinical manifestations in those
with and without PAH are summarised in Table 1.
Patients with SSc-PAH had significantly lower health
related quality of life scores in all domains of the SF-
36 form compared with SSc patients without PAH
(Table 1).
Features found more commonly in patients with
PAH included gastrointestinal manifestations such as
oesphageal stricture, bowel dysmotility and anal in-
continence, pericardial effusion, joint contractures,
calcinosis, digital ulcers, sicca symptoms, mild ILD,
higher modified Rodnan skin score and telangiectasia
(all p < 0.01)
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Clinical variables predictive of developing SSc-PAH
In univariable analysis, clinical variables associated with the
development of PAH included gastrointestinal manifesta-
tions such as oesphageal stricture, bowel dysmotility, anal
incontinence, joint contractures, calcinosis, digital ulcers,
sicca symptoms, mild ILD, telangiectasia, disease duration
at recruitment and the absence of anti-topoisomerase I
(Scl-70) antibody (Table 2).
Using multivariable logistic regression together with post-
estimation diagnostics, we were able to determine the asso-
ciations of different combinations of risk factors with the
development of SSc-PAH. We created a six variable model
for the prediction of PAH in patients with SSc. These clin-
ical variables and their associated odds ratios for develop-
ment of PAH are presented in Table 3. ACA was associated
with a 1.6-fold increased odds of developing SSc-PAH,
oesphageal stricture with 2-fold increased odds, calcinosis
with a 1.9-fold increased odds, digital ulcers with a 1.6-
fold increased odds, mild ILD with a 2.3-fold increased
odds and sicca symptoms with a 1.6-fold increased odds
of PAH. This six variable model had an area under the
curve of 0.70, goodness of fit p = 0.28 and concordance of
91.8 %. The sensitivity, specificity, PPV and NPV of this
Table 1 Characteristics of patients with and without SSc-PAH
(n = 1579)
PAH No PAH p
n = 132 n = 1447
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Anti-centromere pattern ANA 63 (51.6 %) 584 (43.6 %) 0.10
Scl 70 positive 9 (7.4 %) 189 (14.1 %) 0.04
Antiphospholipid antibody 33 (27.1 %) 292 (21.8 %) 0.12
RNA polymerase III positive 8 (11.4 %) 100 (12.4 %) 0.57











































































































Abbreviations: GAVE gastric antral vascular ectasia, ILD interstitial lung disease,
PAH pulmonary arterial hypertension
adisease duration from first non-Raynaud manifestation
Table 2 Univariable logistic regression analysis
Predictors of PAH OR (95 % CI) p
GAVE 1.42 (0.8–2.5) 0.21
Reflux oesphagitis 1.07 (0.8–1.5) 0.71
Oesphageal stricture 2.59 (1.7–4.0) <0.001
Oesphageal dysmotility 1.43 (0.8–2.5) 0.20
Bowel dysmotility 1.47 (1.0–2.2) 0.05
Anal incontinence 1.66 (1.1–2.5) 0.01
Myocardial 1.14 (0.6–2.2) 0.70
Pericardial effusion 4.44 (2.7–7.4) <0.001
Renal crisis 0.59 (0.2–2.5) 0.47
Synovitis 0.96 (0.6–1.5) 0.86
Joint contractures 1.79 (1.2–2.6) 0.002
Calcinosis 2.65 (1.8–3.9) <0.001
Digital Ulcers 1.85 (1.3–2.7) 0.001
Sicca symptoms 2.23 (1.5–3.4) <0.001
ILD 1.95 (1.4–2.8) <0.001
Telangiectasia 3.02 (1.5–6.0) 0.002
Disease duration at recruitment 1.03 (1.01–1.05) <0.001
Limited systemic sclerosis 1.13 (0.8–1.7) 0.54
Autoantibodies
Anti-centromere pattern 1.36 (0.9–1.9) 0.11
Scl 70 + ve 0.49 (0.2–0.9) 0.05
RNA polymerase III + ve 0.89 (0.4–1.9) 0.78
Abbreviations: GAVE gastric antral vascular ectasia, ILD interstitial lung disease,
PAH pulmonary arterial hypertension
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model are 100 % (95 % CI 99.7–100 %), 99.9 % (95 % CI
99.3–99.9 %), 100 % (95 % CI 15.8–100 %) and 91.8 %
(95 % CI 90.3–93.1 %), respectively. While only 2 patients
with PAH had all six variables present, the presence of any
four or more of the six risk factors gave predictive proper-
ties similar to those presented for the complete model
(Additional file 1).
Clinical variables predictive of SSc-PAH according to disease
subtype
By using multivariable logistic regression along with post-
estimation diagnostics and analysing by disease subtype, we
created PAH predictive models for each disease subtype.
For lcSSc, we created a four clinical variable model for
the prediction of PAH (Table 4). Calcinosis was associated
with a 2.2-fold increased odds of PAH, sicca symptoms
with a 2.6-fold increased odds, mild ILD with a 2.3-fold
increased odds and digital ulcers with a 1.9-fold increased
odds of developing PAH. This model has an area under
the curve of 0.73 with a goodness of fit p = 0.96 and con-
cordance of 89.6 %. The sensitivity, specificity, PPV and
NPV of this model are 7.7 % (95 % CI 3.2–15.2 %), 97.4 %
(95 % CI 96.2–98.3 %), 21.9 % (95 % CI 9.3–40.0 %) and
91.7 % (95 % CI 89.9–93.4 %). Thirty-two of 91 (35.2 %)
patients with lcSSc and PAH had all 4 variables.
For dcSSc, we created a three clinical variable model
for the prediction of PAH (Table 5). Oesphageal stricture
was associated with a 4.4-fold increased odds of PAH,
mild ILD with a 2.8-fold increased odds and the pres-
ence of ACA was associated with a 5.2-fold increased
odds of developing PAH. This model has an area under
the curve of 0.73, goodness of fit p = 0.79 and concord-
ance of 92.7 %. The sensitivity, specificity, PPV and NPV
of this model are 6.7 % (95 % CI 0.8–22.1 %), 100 %
(95 % CI 99–100 %), 100 % (95 % CI 15.8–100 %), and
92.7 % (95 % CI 89.6–95.1 %). However, only 2 of 30
(7 %) patients with dcSSc and PAH had all 3 variables.
Discussion
In this cohort of Australian SSc patients, PAH occurred
with a prevalence of 8.4 %, more frequently in women
(84.9 %) and those with limited disease subtype (68.9 %)
and longer disease duration [14.4 (±12) years], which is
consistent with reports in the literature [14, 15]. Addition-
ally in our cohort, patients’ mean age at PAH diagnosis was
62.7 (±10.3) years. The literature suggests a two fold in-
creased risk of PAH in those diagnosed with SSc over the
age of 60 years compared with those under the age of
60 years [16]. This may reflect progressive vasculopathy
related to longer disease duration and increasing age. The
high frequency of PAH in women has been hypothesised to
be a consequence of decreasing oestrogen levels and loss of
their protective vascular effects in the postmenopausal state
[17]. This has led to the investigation of hormone replace-
ment therapy in the prevention and treatment of PAH [18].
It is important to note that in the model for all SSc pa-
tients, irrespective of disease subtype, the presence of
any four or more of the six variables listed is associated
with a substantially increased risk of developing PAH,
and that patients need not have all of the six variables
present to be deemed ‘at risk’.
Historically, SSc-PAH was thought to predominantly
affect patients with lcSSc [19]. However, our study and
others have shown that it may also occur in patients
with dcSSc [20]. Although the literature suggests that in-
creasing disease duration is associated with increasing
risk of PAH, as in our cohort, other studies have shown
that PAH can occur early, in about 25–50 % of SSc pa-
tients within the first five years of the first SSc-related
non Raynaud’s manifestation [21, 22].
Vasculopathy is a characteristic component of SSc.
Therefore it is not surprising that obliterative vascu-
lopathy of the pulmonary microvasculature, as occurs
in PAH, would be associated with vasculopathy of the
peripheral microvasculature resulting in severe Raynaud’s
phenomenon, digital ulcers and digital amputation. In keep-
ing with the literature [23], we showed a strong association
between digital ulcers and PAH in our SSc model and also
in the lcSSc model. However, this association was not seen
Table 3 Multivariable analysis of predictors of PAH in SSc
Predictors of PAH OR (95 % CI) p
Presence of anticentromere antibody 1.63 (1.1–2.5) 0.03
Oesphageal stricture 2.00 (1.2–3.3) 0.01
Calcinosis 1.88 (1.2–2.9) 0.01
Digital Ulcers 1.56 (1.0–2.4) 0.03
ILD 2.34 (1.5–3.7) <0.001
Sicca 1.62 (1.1–2.5) 0.03
Abbreviations: ILD interstitial lung disease, PAH pulmonary arterial hypertension
Table 4 Multivariable analysis of predictors of PAH in lcSSc
Predictors of PAH OR (95 % CI) p
Calcinosis 2.24 (1.4–3.7) 0.001
Sicca 2.63 (1.5–4.6) 0.001
ILD 2.31 (1.4–3.8) 0.001
Digital Ulcers 1.85 (1.2–3.7) 0.01
Abbreviations: ILD interstitial lung disease, lcSSc limited cutaneous systemic
sclerosis, PAH pulmonary arterial hypertension
Table 5 Multivariable analysis of predictors of PAH in dcSSc
Predictors of PAH OR (95 % CI) p
Oesphageal stricture 4.42 (1.9–10.5) 0.001
ILD 2.83 (1.2–6.8) 0.02
ACA 5.16 (1.8–14.8) 0.002
Abbreviations: dcSSc diffuse cutaneous systemic sclerosis, ILD interstitial lung
disease, PAH pulmonary arterial hypertension, ACA anticentromere antibody
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in the dcSSc model. The reason for this is unclear, but may
relate to worse vasculopathy in those with lcSSc due to
their longer disease duration.
Similarly, telangiectasiae are vascular lesions composed
of vasodilated post-capillary venules without evidence of
neovascularisation or inflammation, that have been re-
ported as a risk factor for the development of SSc-PAH
[24]. In our study, this association was only significant in
univariable analysis. This may be due to a specific pattern
or size of telangiectasia, which is not recorded in our data
set. The pathogenesis is thought to be the consequence of
an aberrant attempt at increasing blood perfusion to hyp-
oxic tissues due to the loss of normal circulation. Thus,
telangiectasiae have been hypothesised to be markers of
ongoing vascular injury and failed vascular repair [24]. As
the disease duration of both patients with and without
PAH in our cohort was quite long [11.1 (±10) years] and
the presence and frequency of telangiectasiae is known to
be strongly associated with disease duration, this may ex-
plain why we did not show a significant association with
telangiectasia in those with PAH.
Calcinosis is the deposition of calcium in the skin and
subcutaneous tissues occurring in about 22 % of SSc pa-
tients. Local trauma, chronic inflammation and vascular
hypoxia secondary to vasculopathy of the dermal and
subcutaneous microvasculature with subsequent tissue
hypoxia have been hypothesised to be the main underlying
pathogenic mechanisms causing an increased calcium in-
flux into cells [25]. Hence, the association between calcino-
sis and PAH as we and others have shown is plausible [25].
Chronic, silent micro-aspiration, usually as a result of
untreated gastro-oesphageal reflux disease (GORD), is a
cause of significant morbidity and mortality. Chronic, un-
treated GORD and micro-aspiration can result in oespha-
geal strictures. The aetiology behind the strong associated
between oesphageal strictures and SSc-PAH in our study is
unclear. We know from the lung transplant literature that
micro-aspiration is a significant risk factor in the develop-
ment of bronchiolitis obliterans and subsequent transplant
failure [26]. So much so that it is recommended that all pa-
tients be screened with oesphageal pH manometry prior to
being considered for transplantation [27]. We postulate that
this may be due to an inflammatory cytokine milieu caused
by micro-aspiration and GORD initiating a cascade of in-
flammation, remodelling and fibrosis within the pulmonary
vasculature leading to PAH. This microvascular reaction
leading to PAH may be the same reactive process oc-
curring in the microvascular bed, causing damage to
the oesophageal muscle or neurological plexus resulting
in the motility disorder causing GORD. Additionally,
overnight hypoxaemia secondary to aspiration from GORD
may contribute as a driver of PAH.
Furthermore, GORD and chronic, silent micro-aspiration
have been implicated in the pathogenesis and natural
history of ILD, with GORD occurring in ILD with a
prevalence of 90 % [28]. These are areas where further
research is required to elucidate key pathophysiologic
relationships. Additionally, the routine use of proton
pump inhibitors in all patients with SSc, not only those
symptomatic of GORD (given the poor predictive power
of patient reported symptoms) should be considered.
SSc-ILD is a frequent manifestation of SSc, occurring
in up to 75 % of patients overall but leading to end stage
respiratory failure in only a proportion [29]. The patho-
genesis is not well understood, but is thought to be the
consequence of a combination of inflammation, fibrosis
and cell proliferation leading to increased production of
extra-cellular matrix proteins by fibroblasts [29]. SSc-ILD
can occur in isolation or in combination with PAH, where
PAH is a direct consequence of severe ILD (Group 3 PH
which we excluded in this study) or where the two patholo-
gies co-exist (PAH and mild ILD not sufficient enough to
cause PH). The co-existence PAH and mild ILD occurs in
about 25 % of patients with SSc-ILD [29]. The presence of
anti-phospholipid antibodies, particularly anti-cardiolipin
antibodies, is a risk factor for developing co-existent mild
ILD and PAH [30]. In this study, we excluded patients with
severe ILD (FVC < 60 % and abnormal HRCT) in whom
pulmonary hypertension may have occurred secondary to
ILD. However, we found that mild ILD, which in itself was
not significant enough to cause PAH, was a risk factor for
the subsequent development of PAH, perhaps suggesting a
shared underlying pathogenic mechanism.
Sicca symptoms are common in SSc and are explained
by fibrosis of the exocrine glands. They are significant
contributors to poor health related quality of life. The asso-
ciation between sicca symptoms and PAH has been investi-
gated in studies before with conflicting results [31, 32] but
these studies had low patient numbers and may have been
underpowered. Sicca symptoms, particularly xerostomia,
are associated with varying degrees of oesphageal motor
dysfunction regardless of patient reported dysphagia [33].
Accordingly, we propose that this association between sicca
symptoms and PAH may be a consequence of micro-
aspiration secondary to oesphageal dysmotlility.
Certain autoantibodies in SSc are associated with a higher
risk of developing SSc-PAH. These include ACA [34], anti-
phospholipid antibodies [35], anti-U1-ribonucleoprotein
antibodies [36], nucleolar pattern of antinuclear antibodies
[36], anti-endothelial antibodies [37] and anti-4-sulfated N-
acetyllactosamine antibodies [38]. Testing for these last two
autoantibodies is not yet clinically available. In our
study, the presence of ACA and the absence of anti-
topoisomerase I (Scl-70) antibody were associated with
a higher risk of PAH. The association between PAH
and the absence of anti-topoisomerase I (Scl-70) anti-
body has been reported previously [23]. Of interest to
us was the strong association between the presence of
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ACA and the development of PAH in dcSSc. This associ-
ation was not shown in the lcSSc model, perhaps because of
the high prevalence of ACA in almost all patients with lcSSc.
This is a novel finding and we propose that this may be due
to a more ‘CREST’ (calcinosis, Raynaud’s phenomenon,
oesphageal dysmolity, sclerodactyly and telangiectasia)
like profile in these dcSSc patients.
Given the significant burden of disease associated with
SSc-PAH, it is not surprising that patients have worse
health related quality of life scores in all domains in the
SF-36 form. This finding is consistent with the literature
[5] and the introduction of vasodilator therapy has shown
improvement in patient’s quality of life [39].
As presented, we propose predictive models for SSc-PAH
based solely on clinical manifestations and autoantibody
status, which to our knowledge, has not before been re-
ported in the literature. Whilst these models are not
screening or diagnostic models, they can aid in identify-
ing patients who are at an appreciably higher risk of
developing SSc-PAH who should be monitored and
undergo annual screening for PAH. These patients are
also potential candidates for PAH preventive therapy
once this becomes available in the future.
We recognise that there are limitations to our study.
Our study was cross-sectional in nature and undertaken
in a predominantly ‘prevalent’ SSc cohort. Future studies
evaluating predictors of PAH in a purely incident SSc
cohort would be highly informative. In addition, as RHC
was not performed in every patient at every visit, it is
possible that some patients who did not undergo RHC
were misclassified as not having PAH. However, RHC
was performed in almost all patients ‘at risk’ of PAH
based on screening echocardiography and the likelihood of
missed cases of PAH is therefore very low.
Conclusions
Pulmonary arterial hypertension is the leading causes
of SSc-related death. With the advent of potent pul-
monary vasodilators and their associated impact on
patients’ symptoms, quality of life and survival, it is
imperative that we begin to detect PAH in its early
stages to optimise care. We have introduced clinico-
serologic models for prediction of PAH. Interestingly,
the clinical-serologic risk factors for PAH differ based
on disease subtype. In both subtypes, mild ILD is asso-
ciated with PAH, suggesting possible common patho-
genic mechanisms underlying both of these disease
manifestations. Whilst not a screening or diagnostic
model, these models help to identify a subset of
patients at an appreciably higher risk of developing
PAH, who should be screened and would in future
benefit from preventative therapies when these be-
come available.
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